Axsome Therapeutics IPO Info
Company Name: Axsome Therapeutics
Stock Symbol: AXSM
Exchange: NASDAQ
Status: Priced
IPO Date: 11/19/2015
IPO Price:
9.00 (
3.00%)
Underwriters
Ladenburg Thalmann, Cantor Fitzgerald & Co., Brean Capital
Amount of Offering: N/A
Number of Shares Offered: 5.667 Mil
Shares Outstanding After Offering: N/A
Valuation: N/A
Company Description
We are a clinical stage biopharmaceutical company developing novel therapies for the management of pain and other central nervous system, or CNS, disorders. By focusing on this therapeutic area, we are addressing significant and growing markets where current treatment options are limited or inadequate. Our product candidate portfolio includes two late-stage candidates, AXS-02 and AXS-05, which we are developing for multiple indications. We recently initiated a Phase 3 trial with AXS-02 in complex regional pain syndrome and plan to initiate a Phase 3 trial in knee osteoarthritis associated with bone marrow lesions in or before the first quarter of 2016 pursuant to a Special Protocol Assessment, or SPA. We also plan to initiate a Phase 3 trial with AXS-05 in treatment resistant depression in or before the first quarter of 2016. We aim to become a fully integrated biopharmaceutical company that develops and commercializes differentiated therapies that expand the treatment options available to caregivers and improve the lives of patients living with pain and other CNS disorders.
News Headlines
